Factor XI Levels in Acute Ischemic Stroke
The purpose of this study is to evaluate the utility of measuring coagulation factor activities in the setting of acute ischemic stroke, as potential markers of inherited thrombotic risk. The investigators will determine if relationships exist between coagulation factors, including factor VIII, factor IX, and factor XI and clinical diagnosis, classification, and outcome. The investigators will determine if any significant elevations of these factor activities are independent thrombotic risk factors.
Null Hypothesis: There is no statistical difference between coagulation factors, including factors VIII, IX, or XI activity levels in patients having acute ischemic stroke as compared to acute stroke mimics.
|Study Design:||Observational Model: Case Control
Time Perspective: Retrospective
|Official Title:||Factor XI Levels in Acute Ischemic Stroke|
- To determine the relationship between elevated factors VIII, IX and XI and acute ischemic stroke as compared to other emergent events. [ Time Frame: At time of incident stroke (baseline) and at early follow-up (30-60 Days post stroke). ]
- To determine the relationship between elevated factors VIII, IX and XI and stroke subtype. [ Time Frame: 30-60 Days post stroke ]
- To determine if a relationship exists between elevated factors VIII, IX and XI and the clinical severity and stroke outcome. [ Time Frame: 30-60 Days post stroke ]
- To determine if factors VIII, IX and XI level are different in the acute phase of ischemic stroke relative to chronic phase. [ Time Frame: 30-60 Days post stroke ]
- To determine if a relationship exists between factors VIII, IX and XI levels and early stroke/TIA recurrence. [ Time Frame: 30-60 Days post stroke ]
Biospecimen Retention: Samples With DNA
|Study Start Date:||May 2009|
|Study Completion Date:||July 2011|
|Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
Factors VIII, IX and XI levels measured
Non Stroke patients
This is the control group. This group represents patients who were initially evaluated for stroke.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00890812
|United States, Utah|
|University of Utah Health Sciences Center|
|Salt Lake City, Utah, United States, 84132|
|Principal Investigator:||Jennifer Majersik, MD||University of Utah|